UNSPSC 51281804: Carubicin

This classification denotes an anthracycline antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E7437K3983. European Medicines Agency schedules Carubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06151MIG. Carubicin generally arises in the molecular formula C26H27NO10.

UNSPSC 51281804 Carubicin is a Commodity code that captures pharmaceutical procurement activity by state and local health agencies, though recent state and local contract opportunities tagged to this code do not align with carubicin itself. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for the supply of Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets on an Invitation for Bid basis—a completed award, not an open solicitation. State and local health departments and counties use pharmaceutical commodity codes to procure medications and related health supplies through cooperative purchasing vehicles and direct IFB processes, often bundling multiple products and establishing multi-year contracts with renewal options.

Geographic activity centers on Illinois and Florida based on recent postings. The Illinois Department of Public Health used cooperative purchasing to supply antibiotics statewide under a 12-month initial term with two renewal years. Seminole County, Florida posted an IFB in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; that procurement, potentially FEMA-funded, required electronic submission and included standard compliance provisions such as drug-free workplace certification and E-Verify. The Carubicin code itself shows minimal recent activity aligned with its nominal scope—the opportunities currently tagged to it reflect broader pharmaceutical supply procurement rather than carubicin-specific demand.